872044-70-7

Basic information

• Product Name: AN-0128
• Synonyms: AN-0128;ZTLSOLUCMQEGEA-UHFFFAOYSA-N
• CAS NO: 872044-70-7
• Molecular Formula: C20H16BCl2NO3
• Molecular Weight: 400.06294
• Mol File: 872044-70-7.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: AN-0128(CAS DataBase Reference)
• NIST Chemistry Reference: AN-0128(872044-70-7)
• EPA Substance Registry System: AN-0128(872044-70-7)

Safety Data

• Hazardous Substances Data: 872044-70-7(Hazardous Substances Data)

Usage

General Description

AN-0128, also known as tofacitinib, is a Janus kinase (JAK) inhibitor. It is a small molecule drug that works by blocking certain enzymes in the body that are involved in the inflammatory process. This makes it a promising treatment option for inflammatory skin conditions such as psoriasis and atopic dermatitis. AN-0128 has been shown to reduce the production of inflammatory cytokines, leading to a decrease in skin inflammation and improved symptoms. It is typically applied topically and has demonstrated good efficacy with a favorable safety profile in clinical trials. Overall, AN-0128 has shown promise as a potential treatment for inflammatory skin conditions.

Upstream product

• 874-24-8 3-hydroxypyridine-2-carboxylic acid 
• 83846-48-4 3-chloro-4-methyliodobenzene 
• 515157-47-8 B,B-bis(3-chloro-4-methylphenyl)borinic acid 

Relevant articles and documents

Design, Synthesis and Evaluation of Oxazaborine Inhibitors of the NLRP3 Inflammasome

The NLRP3 inflammasome is an important regulator of the sterile inflammatory response, and its activation by host-derived sterile molecules leads to the intracellular activation of caspase-1, processing of the pro-inflammatory cytokines interleukin-1β (IL-1β)/IL-18, and pyroptotic cell death. Inappropriate activation of NLRP3 drives a chronic inflammatory response and is implicated in several non-communicable diseases, including gout, atherosclerosis, type II diabetes and Alzheimer's disease. In this study, we report the design, synthesis and biological evaluation of novel boron compounds (NBCs) as NLRP3 inflammasome inhibitors. Structure–activity relationships (SAR) show that 4-fluoro substituents on the phenyl rings retain NLRP3 inhibitory activity, whereas more steric and lipophilic substituents diminish activity. Loss of inhibitory activity is also observed if the CCl3 group on the oxazaborine ring is replaced by a CF3 group. These findings provide additional understanding of the NBC series and will aid in the development of these NLRP3 inhibitors as tool compounds or therapeutic candidates for sterile inflammatory diseases.

Topical formulations of borinic acid antibiotics and their methods of use

Disclosed are topical formulations, for example, creams, gels, or lotions, of borinic acid antibiotic compounds active against acne vulgaris or secondarily infected skin conditions.

Anti-viral uses of borinic acid complexes

Compositions and methods of use of borinic acid complexes, especially hydroxyquinoline, imidazole and picolinic acid derivatives, as anti-viral agents as well as therapeutic agents for the treatment of diseases caused by viruses are described.